Palo Alto – April 17, 2018 – Cooley advised Unchained Labs on its acquisition of rap.ID, a leading provider of systems used for particle identification in biopharmaceutical development and quality control, as well as its concurrent Series D financing round. Partner Mark Weeks led the Cooley team advising Unchained Labs.
Rap.ID’s Single Particle Explorer is the only tool available to identify particles by their shape and then forensically identify them by their chemical and elemental fingerprints. Rap.ID’s Layer Explorer lets researchers measure the thickness and consistency of silicone oil, which makes it easier to dispense drugs from injectable devices.
“These products are great additions to our biologics tools arsenal. We can now help our customers identify the source of any particle that shows up in their process,” said Tim Harkness, founder and CEO of Unchained Labs, in a news release. “This acquisition expands our portfolio firmly downstream into biologic quality control.”
Based in Pleasanton, California, Unchained Labs helps biologics researchers break free from tools that just don't cut it. Since its founding, the company has grown to more than 180 employees with $50M+ in revenue, nine product lines and direct distribution around the world.
The acquisition of rap.ID marks the sixth acquisition on which Cooley has represented Unchained Labs since helping form the company in 2014.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has 900+ lawyers across 13 offices in the United States, China and Europe.